BLACK WEEKSVials −15% · kits −10% · rest −5%met codeGratis verzending binnen Duitsland vanaf €200

Deze pagina is automatisch vertaald en kan fouten bevatten. Ben je moedertaalspreker? We horen graag je feedback en verbeteringen.Feedback sturen

The Peptide Desk The Peptide Desk
Survodutide, productfoto
GLP-1

Survodutide

GLP-1

  • Verzonden vanuit Duitsland

Bestelling

Stukprijs - Gratis verzending binnen Duitsland vanaf €200 tijdens de Black Weeks
  • DHL met tracking
  • Discrete verpakking

4.6 van 5 op Trustpilot73 reviews

Ook gezocht als: Survodutid · BI 456906

In één oogopslag

Survodutide in cijfers

De kerncijfers uit ons lexicon.

Volledig lexiconartikel
Class
GLP-1 / glucagon dual agonist
Half-life
Several daysweekly dose
Frequency
Once weeklysubcutaneous
Form
Lyophilised powderreconstituted with BAC water
Sizes
10 mg1 size in the shop
  1. up to~15 %

    Phase 2 study in obesity (dose-dependent, up to ~15% weight reduction at 46 weeks) (opens in a new tab)

    le Roux et al., Lancet Diabetes & Endocrinology, 2024
  2. Phase 2 study in MASH and liver fibrosis (opens in a new tab)

    Sanyal et al., New England Journal of Medicine, 2024
  3. Phase 3 trial SYNCHRONIZE-1 in obesity without diabetes (725 adults, 76 weeks) (opens in a new tab)

    le Roux et al., New England Journal of Medicine, 2026

Er is nog geen labanalyse voor Survodutide. Stem eropLaat het zelf testen, wij betalen de helftAlle labanalyses

Kennis

Alles over Survodutide

Handig om erbij te hebben

Wat je erbij nodig hebt

Bacteriostatisch water wordt automatisch aan je winkelwagen toegevoegd. Spuiten en doekjes met één klik.

Insulinespuiten

10 stuks · 5.50 €

Alcoholdoekjes

50 stuks · 10 €

Hoeveel water?

Eenheden op de spuit voor jouw vialgrootte.

Naar de calculator →

FAQ

Veelgestelde vragen

Bronnen bij elk antwoord: lexiconartikel

Nog een vraag?

Schrijf ons, ons team helpt je verder.

Is Survodutide approved?

No. ChEMBL lists Survodutide with phase 3 as the highest phase. The first phase 3 trials (SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD) are finished and were published in 2026, others are still running. The information here describes the state of research and is not a recommendation for use.

How does Survodutide differ from Semaglutide and Retatrutide?

The receptors. Semaglutide acts only on the GLP-1 receptor, Survodutide also on the glucagon receptor, Retatrutide additionally on GIP. The glucagon part acts mainly in the liver, which is why Survodutide is also tested in fatty liver. In a phase 2 trial in type 2 diabetes the higher levels lowered weight more than semaglutide after 16 weeks.

What did the phase 3 trials show?

In SYNCHRONIZE-1 (without diabetes) weight fell by 12.2 and 13.0 percent after 76 weeks, by 5.4 percent on placebo. In SYNCHRONIZE-2 (with type 2 diabetes) it was 8.2 and 9.8 versus 3.9 percent, HbA1c fell by 0.9 and 0.8 percentage points. In SYNCHRONIZE-MASLD liver fat fell by at least 30 percent in 68.5 percent, on placebo in 28.6 percent.

What is known about the liver?

In a phase 2 trial with biopsy MASH improved without worsening of fibrosis in 43 to 62 percent depending on the dose, in 14 percent on placebo. Fibrosis improved in 34 to 36 versus 22 percent. A study in liver cirrhosis tested uptake and tolerability. Two large phase 3 trials on MASH are still running.

How high were the doses in trials?

The highest study dose was 6 mg per week, in the liver trial and the phase 3 programme. All trials raise the dose in steps over weeks. In the phase 2 trial in overweight the effect rose only a little from the second level on. The entry describes the same principle: start low and only increase until an effect is noticeable. This is not a dosing recommendation.

Which side effects were seen?

Mainly gastrointestinal effects, mostly mild to moderate. In SYNCHRONIZE-1 80.9 and 89.7 percent had them, 47.9 percent on placebo. In the liver trial nausea, diarrhoea and vomiting were clearly more common with Survodutide than with placebo. The trials describe the complaints mainly during escalation.

Which trials are still running?

Three of the listed phase 3 trials are still recruiting: LIVERAGE on MASH with fibrosis (planned end 2031), LIVERAGE-Cirrhosis on MASH with cirrhosis and a trial on blood sugar in type 2 diabetes. The large cardiovascular safety trial with 5,531 participants is finished, results had not been published by October 2026.

Gerelateerd

Gerelateerde producten